Press Releases

AbCellera announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). OrthoMab is a clinically validated platform that uses the most advanced computational and experimental protein engineering methods to create IgG-like bispecific antibodies from any two antibody sequences. By integrating OrthoMab into its existing technology stack, AbCellera provides the industry with a rapid and complete solution for generating tailored, stable and developable bispecific

Co-development of urokinase-type plasminogen activator receptor-targeted radiological immunotherapy (RIT) Monopar Therapeutics Inc.(Wilmette, Illinois) and NorthStar Medical Radioisotopes, LLC (Beloit, Wisconsin) for the treatment of patients with severe COVID-19 Established a partnership with Aragen Bioscience, Inc. (Morgan Hill, California), a leading contract research organization that accelerates preclinical bioproduct development. Aragen will conduct research aimed at selecting the main

Genentech, a member of the Roche Group, announced that Genentech and Roche are joining forces with Regeneron in the fight against COVID-19 to develop, manufacture and distribute REGN-COV2, Regeneron’s investigational antiviral antibody combination, to people around the globe. REGN-COV2 could provide a much needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread o

Avacta Group plc , the developer of Affimer® biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, to include new programmes incorporating Avacta’s Affimer XT™ serum half-life extension system. In December 2018, Avacta and LG Chem entered into a multi-target therapeutics development agreement

Eli Lilly and Company and Innovent Biologics, Inc. (HKEX: 01801)  announced a global expansion of their strategic alliance for TYVYT® (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China. In 2019, Lilly and Innovent began commercializing TYVYT in China after being granted marketing approval for relapsed or refractory classic Hodgkin's lymphoma after at least two lines of systemic chemother

HiFiBiO Therapeutics, a multinational biotherapeutics company focused on the development of novel antibodies for immunomodulation, announced a collaboration with the Coronavirus Immunotherapy Consortium (CoVIC), a global, academic-industry, non-profit research alliance headquartered at the La Jolla Institute for Immunology (LJI). CoVIC was established to accelerate discovery, optimization, and delivery of life-saving antibody-based therapeutics against SARS-CoV-2. It has received support from

LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, announced that LG Chem has entered an exclusive license agreement with TransThera, for the development and commercialization of TransThera’s TT-01025, a highly selective oral small molecule inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) that has sh

JN Nova Pharma Inc. has entered into collaboration with the National Research Council of Canada’s (NRC) Pandemic Response Challenge program to develop a therapeutic pipeline for severe pathologies observed in COVID-19. COVID-19 is not ‘just’ a respiratory infection – it is a complex disease that causes damage to multiple organs, including lung, heart, blood vessels and brain. JN Nova Pharma and the NRC’s team from the Human Health Therapeutics Research

Bushu Pharmaceuticals Ltd., one of Japan's largest contract manufacturers of pharmaceutical products, announced on August 14 a major capital program costing $100 million to expand its footprint, capacity and portfolio of services. The program extends over the next five years in order to accommodate client needs. Bushu is nearing completion of its 3,900-square-meter (42,000-sq.-ft.) cold chain warehouse facility at its Misato plant north of Tokyo. The new facility will be commiss

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of contract biopharmaceutical manufacturing and development services, is pleased to announce a major expansion of its small molecule manufacturing capabilities with the addition of a new production facility in Visakhapatnam, India. Construction of the 8,500 square meter facility began at the end of July 2020 and is expected to be completed by mid-2022. To meet current and future customer needs, the new